Comparing how the body absorbs different forms of berobenatide in adults with obesity
Tests how berobenatide enters the blood in adults with obesity.
Plain-language title generated from the registry record
Registry title: A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
Key facts
- Where
- Anaheim, United StatesSee the site
- Phase
- Phase 1
Where in United States
- Anaheim Clinical Trials, LLCAnaheim, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07876531EU 2025-524803-65-00
- Record updated
- 6 November 2026
- Original description
This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy.Read full original descriptionShow less
PHASE 1, SINGLE DOSE, OPEN-LABEL, RANDOMIZED, PARALLEL GROUP, PK COMPARABILITY STUDY BETWEEN DIFFERENT DELIVERY SYSTEMS OF BEROBENATIDE IN ADULTS WITH OVERWEIGHT OR OBESITY
This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy.
The study involves multiple clinic visits at a study site over the length of the study.
Inclusion: Participants 18 years of age or older; BMI of 27-45 kg/m2; and a total body weight >50 kg (110 lb).
Exclusion: Clinically significant gastric emptying abnormality or chronically taking drugs that directly affect gastrointestinal (GI) motility; Acute GI symptoms at screening, Day -1, or prior to administration of study intervention; History of other chronic disorders; Personal or first-degree family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or suspected MTC; Pregnant or breastfeeding women, or those planning pregnancy during the study.